8,394 reports of this reaction
6.0% of all DROSPIRENONE AND ETHINYL ESTRADIOL reports
#4 most reported adverse reaction
DEEP VEIN THROMBOSIS is the #4 most commonly reported adverse reaction for DROSPIRENONE AND ETHINYL ESTRADIOL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 8,394 FDA adverse event reports linking DROSPIRENONE AND ETHINYL ESTRADIOL to DEEP VEIN THROMBOSIS. This represents approximately 6.0% of all 140,358 adverse event reports for this drug.
Patients taking DROSPIRENONE AND ETHINYL ESTRADIOL who experience deep vein thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEEP VEIN THROMBOSIS is moderately reported among DROSPIRENONE AND ETHINYL ESTRADIOL users, representing a notable but not dominant share of adverse events.
In addition to deep vein thrombosis, the following adverse reactions have been reported for DROSPIRENONE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to deep vein thrombosis in FDA adverse event reports:
DEEP VEIN THROMBOSIS has been reported as an adverse event in 8,394 FDA reports for DROSPIRENONE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEEP VEIN THROMBOSIS accounts for approximately 6.0% of all adverse event reports for DROSPIRENONE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience deep vein thrombosis while taking DROSPIRENONE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.